Literature DB >> 15919239

Contrast nephropathy post cardiac resynchronization therapy: an under-recognized complication with important morbidity.

Peter J Cowburn1, Harshna Patel, Rebecca R Pipes, John D Parker.   

Abstract

OBJECTIVES: The aim of the study was to define the incidence of contrast nephropathy in patients undergoing cardiac resynchronization therapy (CRT).
BACKGROUND: CRT is a promising new treatment for advanced heart failure. It is a technically demanding procedure with a recognized failure/complication rate. Contrast nephropathy is a well-recognized complication of coronary angiography/intervention, but has not been described following CRT.
METHODS: We performed a retrospective chart review of patients who had undergone CRT at Mount Sinai Hospital, a tertiary referral center for heart failure management, to define the incidence of contrast nephropathy in patients undergoing CRT. Contrast nephropathy was defined as the occurrence of a 25% or greater increase in serum creatinine within 48 h after contrast administration.
RESULTS: Sixty-eight patients underwent a total of seventy-three procedures between October 1st 2000 and December 31st 2003. Ten patients (14%) developed contrast nephropathy. Three of these patients (4%) required hemofiltration and one died. Patients with creatinine > or = 200 micromol/l (2.26 mg/dl) were more likely to develop contrast nephropathy than those with creatinine < 200 micromol/l (6/14 patients [43%] v 4/59 patients [7%], p<0.01). The mean length of hospital stay post-procedure in patients developing contrast nephropathy was 19+/-18 (SD) days versus 4+/-5 days for those patients with stable renal function (p<0.01).
CONCLUSIONS: Contrast nephropathy is a frequent, but under-recognized complication of CRT with important morbidity/mortality. The extended hospital stay associated with contrast nephropathy has important clinical and health care implications. Patients and physicians need to be aware of this potential risk.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15919239     DOI: 10.1016/j.ejheart.2004.10.023

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  11 in total

1.  Response to Cardiac Resynchronization Therapy Improves Renal Function. Importance of Forward and Backward Failure.

Authors:  Guido Boerrigter; Lisa C Costello-Boerrigter; William T Abraham; Martin G St John Sutton; Denise M Heublein; Kristin M Kruger; Michael R S Hill; Peter A McCullough; John C Burnett
Journal:  J Card Fail       Date:  2009-02-01       Impact factor: 5.712

2.  Deployment of left ventricular lead from the ipsilateral side of central vein obstruction.

Authors:  Klaus K A Witte; Sue J Kelly; John D Parker; Kumaraswamy Nanthakumar
Journal:  J Interv Card Electrophysiol       Date:  2005-06       Impact factor: 1.900

Review 3.  The potential role of cardiac resynchronization therapy in acute heart failure syndromes.

Authors:  Norman C Wang; Sanjoy Bhattacharya; Mihai Gheorghiade
Journal:  Heart Fail Rev       Date:  2011-09       Impact factor: 4.214

Review 4.  Three-dimensional mapping in cardiac implantable electronic device - a feasible and effective alternative to fluoroscopy.

Authors:  Xiaozhen Ge; Mengna Chen; Zhongxin Sha; Junmeng Zhang
Journal:  J Interv Card Electrophysiol       Date:  2022-07-09       Impact factor: 1.900

5.  Clinical risk factors for the prediction of acute kidney injury post cardiac resynchronization therapy in an elderly population.

Authors:  Alexander Marschall; Hugo Del Castillo Carnevalli; José Carlos De la Flor Merino; Miguel Rubio Alonso; Ramón De Miguel Gómez; Jorge Palazuelos Molinero; María de Fatima Goncalves Sánchez; Edurne López Soberon; Concepción Fernández Pascual; Ricardo Concepción Suárez; Dámaris Carballeira Puentes; Freddy Andrés Delgado Calva; Salvador Álvarez Antón; David Martí Sánchez
Journal:  Int J Cardiol Heart Vasc       Date:  2020-07-25

6.  Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rate.

Authors:  Guido Boerrigter; Lisa C Costello-Boerrigter; William T Abraham; Martin G St John Sutton; Denise M Heublein; Kristin M Kruger; Michael R S Hill; Peter A McCullough; John C Burnett
Journal:  J Card Fail       Date:  2008-05-27       Impact factor: 5.712

7.  Implantation of BIV ICD with Near Zero Contrast Use in Patients with Advanced Renal Insufficiency Using Three Dimensional Electro-anatomical Mapping.

Authors:  Adel Mina; Bradley Knight; Nicholas Warnecke
Journal:  J Atr Fibrillation       Date:  2019-12-31

8.  Cardiac resynchronization therapy in the cardiorenal syndrome.

Authors:  Margot K Davis; Sean A Virani
Journal:  Int J Nephrol       Date:  2011-06-09

9.  Contrast-induced acute kidney injury in patients undergoing cardiac resynchronization therapy-incidence and prognostic importance. Sub-analysis of data from randomized TRUST CRT trial.

Authors:  Jacek Kowalczyk; Radoslaw Lenarczyk; Oskar Kowalski; Tomasz Podolecki; Pawel Francuz; Patrycja Pruszkowska-Skrzep; Mariola Szulik; Michal Mazurek; Ewa Jedrzejczyk-Patej; Beata Sredniawa; Zbigniew Kalarus
Journal:  J Interv Card Electrophysiol       Date:  2014-03-14       Impact factor: 1.900

10.  Contrast-induced nephropathy after cardiac resynchronization therapy implant impairs the recovery of ejection fraction in responders.

Authors:  Teresa Strisciuglio; Giuseppe Ammirati; Valerio Pergola; Livio Imparato; Cristina Carella; Elisabeta Koci; Rosaria Chiappetti; Fabio Giovanni Abbate; Vincenzo Mirco La Fazia; Aniello Viggiano; Bruno Trimarco; Antonio Rapacciuolo
Journal:  ESC Heart Fail       Date:  2019-12-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.